Citadel Advisors’s Asensus Surgical, Inc. ASXC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-26,106
Closed -$6K 15710
2024
Q1
$6K Sell
26,106
-27,137
-51% -$7.88K ﹤0.01% 13708
2023
Q4
$17K Buy
+53,243
New +$13.7K ﹤0.01% 12765
2023
Q3
Sell
-46,430
Closed -$16.9K 15352
2023
Q2
$23.4K Buy
+46,430
New +$27.7K ﹤0.01% 12594
2023
Q1
Sell
-44,231
Closed -$30K 15727
2022
Q4
$15.4K Buy
+44,231
New +$18K ﹤0.01% 13333
2022
Q3
Sell
-461,485
Closed -$241K 13849
2022
Q2
$184K Sell
461,485
-1,232,974
-73% -$550K ﹤0.01% 10797
2022
Q1
$1.06M Sell
1,694,459
-191,141
-10% -$147K ﹤0.01% 7548
2021
Q4
$2.09M Buy
1,885,600
+1,686,007
+845% +$2.61M ﹤0.01% 6127
2021
Q3
$369K Buy
199,593
+173,373
+661% +$389K ﹤0.01% 10591
2021
Q2
$83K Sell
26,220
-2,482,798
-99% -$6.21M ﹤0.01% 13056
2021
Q1
$8.15M Buy
+2,509,018
New +$9.09M ﹤0.01% 3295
2020
Q2
Sell
-90,840
Closed -$43.8K 10656
2020
Q1
$32K Buy
+90,840
New +$94.8K ﹤0.01% 9179
2019
Q3
Sell
-10,708
Closed -$146K 9880
2019
Q2
$189K Buy
+10,708
New +$234K ﹤0.01% 8232
2019
Q1
Sell
-13,125
Closed -$440K 10007
2018
Q4
$386K Sell
13,125
-12,966
-50% -$589K ﹤0.01% 6840
2018
Q3
$1.97M Buy
26,091
+17,270
+196% +$1.17M ﹤0.01% 4435
2018
Q2
$500K Buy
+8,821
New +$321K ﹤0.01% 6376
2018
Q1
Sell
-7,474
Closed -$171K 8909
2017
Q4
$188K Buy
+7,474
New +$230K ﹤0.01% 7151
2017
Q3
Sell
-2,975
Closed -$34.6K 8169
2017
Q2
$27K Buy
2,975
+106
+4% +$1.01K ﹤0.01% 7232
2017
Q1
$45K Buy
2,869
+811
+39% +$14.1K ﹤0.01% 7066
2016
Q4
$35K Buy
+2,058
New +$42.2K ﹤0.01% 6952
2015
Q4
Sell
-151,190
Closed -$4.44M 9310
2015
Q3
$4.44M Buy
151,190
+12,801
+9% +$475K ﹤0.01% 2071
2015
Q2
$5.4M Buy
+138,389
New +$6.38M ﹤0.01% 1998

Other funds holding ASXC

Citadel Advisors's ASXC Position: Q2 2024 in Review

Citadel Advisors sold out of Asensus Surgical, Inc. (ASXC) in Q2 2024, closing a stake of 26,106 shares — an estimated $6K sold.

Citadel Advisors first reported a position in ASXC in Q2 2015 and held it in 21 quarters. The position peaked at $8.15M in Q1 2021. 64 funds tracked by Wall St. Rank hold ASXC as of Q2 2024.

  • Citadel Advisors reported no remaining Asensus Surgical, Inc. position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 26,106 Asensus Surgical, Inc. shares in Q2 2024, an estimated $6K.
  • Citadel Advisors first reported a position in Asensus Surgical, Inc. in Q2 2015 and held it in 21 quarters.
  • Citadel Advisors's Asensus Surgical, Inc. position peaked at $8.15M in Q1 2021.
  • 64 funds tracked by Wall St. Rank held Asensus Surgical, Inc. as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.